Avanos Medical (AVNS) grants SVP Delgado stock options and RSUs

Rhea-AI Filing Summary

Avanos Medical SVP Sigfrido Delgado received new equity awards as part of compensation. On March 13, 2026, he was granted employee stock options for 37,520 shares of Common Stock at an exercise price of $13.69 per share, expiring March 13, 2036. These options vest 30% on March 13, 2027, 30% on March 13, 2028 and 40% on March 13, 2029. He was also awarded 15,886 time-based restricted share units, each economically equivalent to one share of Common Stock, vesting one-third on March 13, 2027, one-third on March 13, 2028 and one-third on March 13, 2029. Following these awards, Delgado directly holds 60,005 shares of Common Stock and 59,434 derivative securities.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Delgado Sigfrido

(Last) (First) (Middle)

5405 WINDWARD PKWY

(Street)

ALPHARETTA GA 30004-4667

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AVANOS MEDICAL, INC. [ AVNS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Operations

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		A		15,886(1)	A	$0	60,005	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$13.69	03/13/2026		A		37,520		(2)	03/13/2036	Common Stock	37,520	$0	59,434	D

Explanation of Responses:

1. Represents time-based restricted share units (TRSUs) awarded pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended. The award will vest 1/3 on March 13, 2027, 1/3 on March 13, 2028 and 1/3 on March 13, 2029. Each TRSU is the economic equivalent of one share of Common Stock.

2. The award will vest 30% on March 13, 2027, 30% on March 13, 2028 and 40% on March 13, 2029.

Remarks:

	/s/ John Hurley, as attorney-in-fact for Sigfrido Delgado	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did AVNS executive Sigfrido Delgado receive?

Sigfrido Delgado received stock options for 37,520 shares at a $13.69 exercise price and 15,886 time-based restricted share units. Both awards were granted as compensation and vest in stages between March 2027 and March 2029, aligning his incentives with long-term shareholder value.

When do Sigfrido Delgado’s new AVNS stock options vest?

Delgado’s employee stock options vest in three tranches: 30% on March 13, 2027, 30% on March 13, 2028, and 40% on March 13, 2029. This multi-year schedule encourages retention and long-term focus on Avanos Medical’s operational and financial performance.

How are Sigfrido Delgado’s AVNS restricted share units structured?

The 15,886 time-based restricted share units vest one-third on March 13, 2027, one-third on March 13, 2028, and one-third on March 13, 2029. Each TRSU is economically equivalent to one share of Avanos Medical Common Stock, providing direct equity exposure over time.

Are Sigfrido Delgado’s recent AVNS transactions open-market purchases?

No, the transactions are compensation awards, not open-market purchases. They consist of a grant of employee stock options and time-based restricted share units, both reported at a price of $0.00 per share, reflecting their nature as equity incentives rather than market trades.

What are Sigfrido Delgado’s AVNS holdings after these awards?

After the March 13, 2026 grants, Delgado directly holds 60,005 shares of Avanos Medical Common Stock and 59,434 derivative securities, including the newly granted stock options. These positions reflect his ongoing equity stake as Senior Vice President, Operations at the company.